1 Recommendations

1 Recommendations

1.1 Ceritinib is recommended, within its marketing authorisation, as an option for treating advanced anaplastic lymphoma kinase positive non‑small‑cell lung cancer in adults who have previously had crizotinib. The drug is recommended only if the company provides it with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)